Harris poll: Walgreens tops among drug store retailers in brand equity
NEW YORK — Consumers gravitate toward traditional pharmacies for their everyday health-and-wellness needs, according to the "2012 Harris Poll EquiTrend" survey released Monday. Among retail pharmacy operations, Walgreens enjoyed the greatest brand equity among consumers based on top consumer scores in "familiarity" and "purchase consideration" categories. Overall, Walgreens’ brand equity was tabulated at 69.9, CVS/pharmacy came in at 67.4 and Rite Aid 62.5.
Pharmacies in the "drug store brands" category also included Costco, Kmart, Target and Walmart. This is the first year that Harris Interactive polled consumers around drug store brands.
In the "value retailer" category, Target was rated higher than Walmart. "Top scores for all three elements of brand equity — ‘familiarity,’ ‘quality’ and ‘purchase intention’ — drove this strong performance," Harris Interactive stated. And Costco debuted as the "Gasoline Retail Brand of the Year."
The Harris Interactive consumer survey uses a brand equity model with elements like familiarity, quality and purchase consideration to help quantify a brands’ connection with consumers.
The study was conducted online from Jan. 31 through Feb. 20, 2012, and analyzes the responses of more than 38,500 consumers on key measures of brand health — including how well the public knows a brand, how positively they think of the brand and their consideration to do business with or donate to a brand. Each brand is rated 1,000 times among respondents who are familiar with the brand. Harris Interactive has conducted its EquiTrend study regularly since 1989, and can offer yearly trended data from 2005. The Equity Score, a key takeaway from EquiTrend, has been validated against financial performance by Georgetown University, Harris Interactive stated.
OIG to CMS: Room for improvement in tracking Medicare Part D fraud
WASHINGTON — The Center for Medicare and Medicaid Services needs to beef up its oversight on Medicare Part D submissions from retail pharmacy, according to an Office of Inspector General report published last week.
The OIG suggested CMS strengthen a MEDIC’s ability to track pharmacy billing (MEDICs — Medicare Drug Integrity Contractors — are private organizations who are contracted by CMS to assist in anti-fraud and abuse efforts) and improve compliance plan audits, specifically targeting independent pharmacies and pharmacies in urban locales.
“In responding to the OIG report, policy-makers should proceed carefully to get at the heart of the issue without inadvertently burying pharmacists and patients in unproductive red tape," cautioned Doug Hoey, CEO for the National Community Pharmacists Association, in response to the report. "To bring standards, clarity and consistency to pharmacy audit practices, NCPA supports state and federal reform legislation, including H.R. 4215, the Medicare Pharmacy Transparency and Fair Auditing Act."
According to the report, in 2009, some 4.4% of pharmacies had questionable billing practices around Medicare Part D submissions. Retail pharmacies submitted Medicare Part D claims totaling almost $1 million per store.
All told, 2,637 retail pharmacies were identified as part of an exception report across at least 1-of-8 parameters, the OIG noted. The Miami, Los Angeles and Detroit areas were the most likely to have pharmacies with questionable billing.
"For example, many pharmacies billed extremely high dollar amounts or numbers of prescriptions per beneficiary or per prescriber," the 36-page report read. "This could mean that a pharmacy is billing for drugs that are not medically necessary or were never provided to the beneficiary. Although some of this billing may be legitimate, pharmacies that bill for extremely high amounts warrant further scrutiny."
The eight measures identified in the report include:
Average amount billed per beneficiary;
Average number of prescriptions per beneficiary;
Average amount billed per prescriber;
Average number of prescriptions per prescriber;
Percentage of prescriptions that were for Schedule II drugs;
Percentage of prescriptions that were for Schedule III drugs;
Percentage of prescriptions that were for brand-name drugs; and
Percentage of prescriptions that were refills.
The report noted that pharmacies identified on the exception report were more likely to be independent. "Almost 11% of independent pharmacies had questionable billing, compared to just over 1% of chain pharmacies," the report noted. "Although independent pharmacies made up 34% of all retail pharmacies that billed Part D, they accounted for 80% of the pharmacies with questionable billing."
However, the OIG stopped short of making any suggestion that the retail pharmacies indicated in the exception report were actually engaging in fraudulent or abusive practices. "Some pharmacies may be billing extremely high amounts for legitimate reasons," the OIG acknowledged. "For example, a pharmacy located in a rural area with few physicians may bill for an extremely high average number of prescriptions per prescriber. Alternatively, a pharmacy located next to a pain clinic may bill for an extremely high percentage of Schedule II or III drugs."
“It is important to note that for approximately 96% of community pharmacies, the OIG report identified no ‘questionable’ billing," Hoey said. Hoey identified several more situations that would help explain the proportion of independents on the exception report. "Independent pharmacies serve a disproportionately high number of long-term care and other patients who are prescribed more medications than the average Medicare beneficiary," he said. "[And] many independents are in urban areas near large teaching hospitals or cancer clinics where physicians prescribe a disproportionate share of controlled substances."
Hoey also suggested that individuals actively seeking to defraud Medicare have identified themselves as independent pharmacies "when legitimate pharmacists and most consumers would not consider them as such."
OIG tracked Part D submissions across 59,307 retail pharmacies, representing 90% of the retail pharmacy universe according to the OIG. Of those 39,401 represented chain pharmacies and 19,906 represented independents.
The analysis did not include long-term care pharmacies, mail-order pharmacies or home infusion pharmacies, the OIG noted, as the billing patterns associated with those pharmacies differ than that of a typical retail pharmacy.
For the full OIG report, click here.
Mylan marks Food Allergy Awareness Week
BASKING RIDGE, N.J. — A company that makes an emergency treatment for severe allergic reactions is marking the 15th annual Food Allergy Awareness Week.
Mylan Specialty, a division of drug maker Mylan, said it would support various initiatives to raise awareness of life-threatening food allergies during the special week, which started Sunday and ends Saturday. Mylan Specialty is the maker of EpiPen (epinephrine), used to treat anaphylaxis, a severe allergic reaction that can occur quickly and without warning.
"Life-threatening allergies are an important and growing public health issue, and we are proud to stand with advocacy partners to shine the spotlight on the need for awareness and preparedness during Food Allergy Awareness Week," Mylan CEO Heather Bresch said. "We are especially pleased by the increasing efforts at the federal and state level to encourage schools to develop and implement plans that help protect students with life-threatening allergies, including having immediate access to epinephrine."